Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue Virus

Abstract Objectives The main purpose of this study was to evaluate the anti-SARS-CoV-2 RBD Ig G antibody response in BNT162b2 vaccine recipients who erroneously received vaccine overdose. Methods Measurement of antibody levels at different time-points was performed to define the dynamics of immunization after a wrongly vaccination schedule. Three recipients had no previous evidence of infection and received the first shot of Oxford/AstraZeneca before the Pfizer/BioNTech vaccine. Another patient, formerly infected by SARS-CoV-2, received one shot of BNT162b2 vaccine. Results At day 6 after the second vaccine dose the serum increase of anti-SARS-CoV-2 RBD Ig G antibodies was analogous for the three SARS-CoV-2 naïve recipients. At 14 days the antibody level increased and reached a peak, though displaying a different pattern among the three recipients. At 21 days the serum antibody level started to decrease from its maximum value. The data for the previously infected recipient were in agreement with values found in COVID-19 positive receivers. Thus, after the single prime-dose of vaccine, the elicited antibody response was similar to prime-boost vaccination in naïve recipients. Conclusions This study confirms the efficiency of the BNT162b vaccine in eliciting a sustained antibody response as heterologous boost-vaccine in previously Oxford/AstraZeneca vaccinated recipients, as well as, prime-vaccine in COVID-19 infected receivers. Importantly, the humoral immunity response of recipients was not proportional to the vaccine overdose. Nonetheless, we cannot portray a univocal effect of vaccine overdose concerning anti-SARS-CoV-2 antibody response because the values found especially in the three SARS-CoV-2 naïve subjects were highly heterogeneous.

Download Full-text

A Prime-Boost Vaccination Strategy in Cattle to Prevent Foot-and-Mouth Disease Using a “Single-Cycle” Alphavirus Vector and Empty Capsid Particles

PLoS ONE ◽

10.1371/journal.pone.0157435 ◽

2016 ◽

Vol 11 (6) ◽

pp. e0157435 ◽

Cited By ~ 17

Author(s):

Maria Gullberg ◽

Louise Lohse ◽

Anette Bøtner ◽

Gerald M. McInerney ◽

Alison Burman ◽

...

Keyword(s):

Foot And Mouth Disease ◽

Vaccination Strategy ◽

Mouth Disease ◽

Single Cycle ◽

Boost Vaccination ◽

Empty Capsid ◽

Foot And Mouth

Download Full-text

Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200605000-00020 ◽

2006 ◽

Vol 16 (3) ◽

pp. 1075-1081 ◽

Cited By ~ 15

Author(s):

A. N. Fiander ◽

A. J. Tristram ◽

E. J. Davidson ◽

A. E. Tomlinson ◽

S. Man ◽

...

Keyword(s):

Phase Ii ◽

Hpv Vaccination ◽

Vaccine Trial ◽

Vaccination Strategy ◽

Intraepithelial Neoplasia ◽

Clinical Effectiveness ◽

Clinical Results ◽

Hpv 16 ◽

Boost Vaccination ◽

Clinical Responses

The objective of this study was to determine the clinical effectiveness of a prime-boost human papillomavirus (HPV) vaccine regimen. A nonrandomized phase II prime-boost vaccine trial was conducted. Women with biopsy-proven anogenital intraepithelial neoplasia (AGIN) 3 were vaccinated with three doses of a recombinant fusion protein comprising HPV 16, E6/E7/L2 (TA-CIN) followed by one dose of a recombinant vaccinia virus encoding HPV 16 and 18 E6/E7 (TA-HPV). Clinical responses were evaluated by serial photographs, symptomatology, and biopsies before and after vaccination. Twenty-nine women were vaccinated; 27 with vulval intraepithelial neoplasia 3 and 2 with vaginal intraepithelial neoplasia grade 3. Clinical responses were seen in five women (17%), with one complete and five partial responses. Fifteen women (62%) had symptomatic improvement. No serious adverse effects were recorded. This is the first trial of a prime-boost vaccination regimen using heterologous HPV vaccines (TA-CIN followed by TA-HPV) in the management of AGIN. Since the prime-boost approach in this cohort offered no significant advantages over single TA-HPV vaccination, there are no further studies planned using this protocol. Future studies are warranted to define responders to immunotherapy.

Download Full-text

Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

Arthritis Research & Therapy ◽

10.1186/s13075-020-2124-3 ◽

2020 ◽

Vol 22 (1) ◽

Cited By ~ 1

Author(s):

Per Nived ◽

Göran Jönsson ◽

Bo Settergren ◽

Jon Einarsson ◽

Tor Olofsson ◽

...

Keyword(s):

Antibody Response ◽

Rheumatic Diseases ◽

Vaccination Strategy ◽

Inflammatory Rheumatic Diseases ◽

Link Type ◽

Boost Vaccination ◽

Positive Antibody ◽

Conventional Dmards ◽

Conjugate Vaccination ◽

Positive Antibody Response

Abstract Objective To explore whether a prime-boost vaccination strategy, i.e., a dose of pneumococcal conjugate vaccine (PCV) and a dose of 23-valent polysaccharide vaccine (PPV23), enhances antibody response compared to single PCV dose in patients with inflammatory rheumatic diseases treated with different immunosuppressive drugs and controls. Methods Patients receiving rituximab (n = 30), abatacept (n = 23), monotherapy with conventional disease-modifying antirheumatic drugs (cDMARDs, methotrexate/azathioprine/mycophenolate mofetil, n = 27), and controls (n = 28) were immunized with a dose PCV followed by PPV23 after ≥ 8 weeks. Specific antibodies to 12 serotypes included in both vaccines were determined using a multiplex microsphere immunoassay in blood samples before and 4–8 weeks after each vaccination. Positive antibody response was defined as ≥ 2-fold increase from pre- to postvaccination serotype-specific IgG concentration and putative protective level as IgG ≥ 1.3 μg/mL. The number of serotypes with positive antibody response and IgG ≥ 1.3 μg/mL, respectively, after PCV and PCV + PPV23 were compared within each treatment group and to controls. Opsonophagocytic activity (OPA) assay was performed for serotypes 6B and 23F. Results Compared to single-dose PCV, prime-boost vaccination increased the number of serotypes with positive antibody response in patients with abatacept, cDMARDs, and controls (p = 0.02, p = 0.01, and p = 0.01), but not in patients on rituximab. After PCV + PPV23, the number of serotypes with positive antibody response was significantly lower in all treatment groups compared to controls but lowest in rituximab, followed by the abatacept and cDMARD group (p < 0.001). Compared to PCV alone, the number of serotypes with putative protective levels after PCV + PPV23 increased significantly only in patients in cDMARDs (p = 0.03) and controls (p = 0.001). Rituximab treatment was associated with large reduction (coefficient − 8.6, p < 0.001) and abatacept or cDMARD with moderate reductions (coefficients − 1.9 and − 1.8, p = 0.005, and p < 0.001) in the number of serotypes with positive antibody response to PCV + PPV23 (multivariate linear regression model). OPA was reduced in rituximab (Pn6B and Pn23F, p < 0.001), abatacept (Pn23F, p = 0.02), and cDMARD groups (Pn6B, p = 0.02) compared to controls. Conclusions Prime-boost strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients with inflammatory rheumatic diseases receiving cDMARDs, to some extent in abatacept but not in patients on rituximab. Pneumococcal vaccination should be encouraged before the initiation of treatment with rituximab. Trial registration ClinicalTrials.gov, NCT03762824. Registered on 4 December 2018, retrospectively registered

Download Full-text